Medtronic has received FDA clearance for its Accurian radio-frequency ablation system for nerve tissues; the device is designed to treat chronic pain via a minimally invasive procedure.
A current produced by radio waves heats up small patches of nerves to stop them from sending pain signals. The system also uses advanced software that controls the amount of power delivered and the temperature of the procedure, ensuring more consistent and predictable lesion formations.
Medtronic says that its Accurian platform can perform standard, pulsed, and enhanced ablation procedures, using internally cooled radio frequency probes to create various lesion shapes, sizes, and volumes. It has independent channel control and chip-enhanced probes for easy on-screen identification, and smart features, such as downloadable procedure reports.
Chronic pain is a disabling condition that affects approximately 100 million American adults. The annual treatment cost of chronic pain and related lost productivity is estimated to be $635 billion.